Zenas BioPharma (ZBIO) EBT Margin (2023 - 2026)

Zenas BioPharma (ZBIO) posted quarterly EBT Margin of 337.78% for Q1 2025, up 67.63% quarter-over-quarter from 1043.5% in Q4 2024.

Zenas BioPharma (ZBIO) EBT Margin (2023 - 2026) Analysis & Trends

Zenas BioPharma's EBT Margin history runs 3 years deep, the most recent figure standing at 337.78% for Q1 2025.

In Q1 2025, EBT Margin changed N/A year-over-year to 337.78%; the TTM figure through Dec 2025 stood at 3885.09% (down 75393.0% YoY), while the FY2025 annual figure was 3885.09%, down 75391.0% from the prior year.
EBT Margin for Q1 2025 stood at 337.78%, up from 1043.5% in the prior quarter.
The five-year high for EBT Margin was 71.25% in Q3 2023, with the low at 1043.5% in Q4 2024.
The 3-year median for EBT Margin is 337.78% (2025), against an average of 436.68%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	-11,134.20%

Download Data